Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Apr, 2016 | Pages:
118 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Acinetobacter Infections - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Acinetobacter Infections - Pipeline Review, H1 2016', provides an overview of the Acinetobacter Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acinetobacter Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acinetobacter Infections and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Acinetobacter Infections - The report reviews pipeline therapeutics for Acinetobacter Infections by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Acinetobacter Infections therapeutics and enlists all their major and minor projects - The report assesses Acinetobacter Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Acinetobacter Infections Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Acinetobacter Infections - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Acinetobacter Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Content 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Acinetobacter Infections Overview 8 Therapeutics Development 9 Pipeline Products for Acinetobacter Infections - Overview 9 Pipeline Products for Acinetobacter Infections - Comparative Analysis 10 Acinetobacter Infections - Therapeutics under Development by Companies 11 Acinetobacter Infections - Therapeutics under Investigation by Universities/Institutes 13 Acinetobacter Infections - Pipeline Products Glance 14 Late Stage Products 14 Early Stage Products 15 Acinetobacter Infections - Products under Development by Companies 16 Acinetobacter Infections - Products under Investigation by Universities/Institutes 19 Acinetobacter Infections - Companies Involved in Therapeutics Development 20 Achaogen Inc. 20 Adenium Biotech ApS 21 AmpliPhi Biosciences Corporation 22 Aridis Pharmaceuticals LLC 23 AstraZeneca Plc 24 AvidBiotics Corp. 25 Cellceutix Corporation 26 Emergent BioSolutions Inc. 27 Evaxion Biotech ApS 28 F. Hoffmann-La Roche Ltd. 29 FOB Synthesis, Inc. 30 LegoChem Biosciences, Inc 31 Melinta Therapeutics, Inc 32 MicuRx Pharmaceuticals, Inc. 33 Nosopharm SAS 34 Omnia Molecular Ltd. 35 Pfizer Inc. 36 Phylogica Limited 37 Sarepta Therapeutics, Inc. 38 Sealife PHARMA GMBH 39 Shionogi & Co., Ltd. 40 Techulon, Inc. 41 Tetraphase Pharmaceuticals Inc. 42 Varinel, Inc. 43 Vaxdyn, S.L. 44 Acinetobacter Infections - Therapeutics Assessment 45 Assessment by Monotherapy Products 45 Assessment by Target 46 Assessment by Mechanism of Action 48 Assessment by Route of Administration 50 Assessment by Molecule Type 52 Drug Profiles 54 A-3APO - Drug Profile 54 AA-139 - Drug Profile 56 ACHN-975 Prodrug - Drug Profile 57 Acinetobacter vaccine - Drug Profile 58 Antisense Oligonucleotide for Acinetobacter baumannii Infections - Drug Profile 59 Antisense Oligonucleotide for Acinetobacter baumannii Infections - Drug Profile 60 AR-401 - Drug Profile 61 AvR2-V10 - Drug Profile 62 Biologics for Acinetobacter Baumannii - Drug Profile 64 EV-035 - Drug Profile 65 Fab-001 - Drug Profile 67 FSI-1671 - Drug Profile 68 FSI-1686 - Drug Profile 69 GN-4474 - Drug Profile 70 LCB-010200 - Drug Profile 71 LCB-100200 - Drug Profile 72 MDN-0057 - Drug Profile 73 Monoclonal Antibodies for Gram-Negative Bacterial Infections - Drug Profile 75 MRX-V - Drug Profile 76 NOSO-95179 - Drug Profile 77 OM-011818 - Drug Profile 78 PMX-100 - Drug Profile 79 PMX-1091 - Drug Profile 80 PMX-1142 - Drug Profile 81 PMX-229 - Drug Profile 82 PMX-633 - Drug Profile 83 pneumonia vaccine - Drug Profile 84 RX-05 - Drug Profile 85 RXP-873 - Drug Profile 86 S-649266 - Drug Profile 87 SLP-0901 - Drug Profile 88 SLP-0905 - Drug Profile 89 Small Molecule for Acinetobacter baumannii Infections - Drug Profile 90 Small Molecule for Gram-Negative Nosocomial Infections - Drug Profile 91 Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections - Drug Profile 92 Small Molecule to Target Bacterial Cell Membrane for Acinetobacter Infections - Drug Profile 93 Small Molecules for Acinetobacter baumannii Infection - Drug Profile 94 Small Molecules for Acinetobacter Infections - Drug Profile 95 Small Molecules for Bacterial Infections - Drug Profile 96 Small Molecules for Multi-Drug Resistant Bacterial Infections - Drug Profile 97 Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile 98 Small Molecules to Inhibit Aminoacyl-tRNA Synthetases for Bacterial Infections - Drug Profile 99 Small Molecules to Inhibit LpxC for Gram-Negative Bacterial Infections - Drug Profile 100 Small Molecules to Inhibit NDH-1 for Acinetobacter baumannii Infections - Drug Profile 101 Synthetic Peptide for Gram-Negative Bacterial Infections - Drug Profile 102 TP-6076 - Drug Profile 103 VAR-10100 - Drug Profile 104 VXD-001 - Drug Profile 105 VXD-003 - Drug Profile 106 Acinetobacter Infections - Recent Pipeline Updates 107 Acinetobacter Infections - Dormant Projects 112 Appendix 114 Methodology 114 Coverage 114 Secondary Research 114 Primary Research 114 Expert Panel Validation 114 Contact Us 114 Disclaimer 115
List of Tables
Number of Products under Development for Acinetobacter Infections, H1 2016 12 Number of Products under Development for Acinetobacter Infections - Comparative Analysis, H1 2016 13 Number of Products under Development by Companies, H1 2016 14 Number of Products under Development by Companies, H1 2016 (Contd..1) 15 Number of Products under Investigation by Universities/Institutes, H1 2016 16 Comparative Analysis by Late Stage Development, H1 2016 17 Comparative Analysis by Early Stage Development, H1 2016 18 Products under Development by Companies, H1 2016 19 Products under Development by Companies, H1 2016 (Contd..1) 20 Products under Development by Companies, H1 2016 (Contd..2) 21 Products under Investigation by Universities/Institutes, H1 2016 22 Acinetobacter Infections - Pipeline by Achaogen Inc., H1 2016 23 Acinetobacter Infections - Pipeline by Adenium Biotech ApS, H1 2016 24 Acinetobacter Infections - Pipeline by AmpliPhi Biosciences Corporation, H1 2016 25 Acinetobacter Infections - Pipeline by Aridis Pharmaceuticals LLC, H1 2016 26 Acinetobacter Infections - Pipeline by AstraZeneca Plc, H1 2016 27 Acinetobacter Infections - Pipeline by AvidBiotics Corp., H1 2016 28 Acinetobacter Infections - Pipeline by Cellceutix Corporation, H1 2016 29 Acinetobacter Infections - Pipeline by Emergent BioSolutions Inc., H1 2016 30 Acinetobacter Infections - Pipeline by Evaxion Biotech ApS, H1 2016 31 Acinetobacter Infections - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 32 Acinetobacter Infections - Pipeline by FOB Synthesis, Inc., H1 2016 33 Acinetobacter Infections - Pipeline by LegoChem Biosciences, Inc, H1 2016 34 Acinetobacter Infections - Pipeline by Melinta Therapeutics, Inc, H1 2016 35 Acinetobacter Infections - Pipeline by MicuRx Pharmaceuticals, Inc., H1 2016 36 Acinetobacter Infections - Pipeline by Nosopharm SAS, H1 2016 37 Acinetobacter Infections - Pipeline by Omnia Molecular Ltd., H1 2016 38 Acinetobacter Infections - Pipeline by Pfizer Inc., H1 2016 39 Acinetobacter Infections - Pipeline by Phylogica Limited, H1 2016 40 Acinetobacter Infections - Pipeline by Sarepta Therapeutics, Inc., H1 2016 41 Acinetobacter Infections - Pipeline by Sealife PHARMA GMBH, H1 2016 42 Acinetobacter Infections - Pipeline by Shionogi & Co., Ltd., H1 2016 43 Acinetobacter Infections - Pipeline by Techulon, Inc., H1 2016 44 Acinetobacter Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2016 45 Acinetobacter Infections - Pipeline by Varinel, Inc., H1 2016 46 Acinetobacter Infections - Pipeline by Vaxdyn, S.L., H1 2016 47 Assessment by Monotherapy Products, H1 2016 48 Number of Products by Stage and Target, H1 2016 50 Number of Products by Stage and Mechanism of Action, H1 2016 52 Number of Products by Stage and Route of Administration, H1 2016 54 Number of Products by Stage and Molecule Type, H1 2016 56 Acinetobacter Infections Therapeutics - Recent Pipeline Updates, H1 2016 110 Acinetobacter Infections - Dormant Projects, H1 2016 115 Acinetobacter Infections - Dormant Projects (Contd..1), H1 2016 116
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
